Literature DB >> 28849690

Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement.

Laura S Hiemcke-Jiwa1, Roos J Leguit1, Joyce H Radersma-van Loon1, Peter E Westerweel2, Johannes J M Rood3, Jeanette K Doorduijn4, Manon M H Huibers1, Monique C Minnema5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28849690     DOI： 10.1080/10428194.2017.1369074

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma.

Authors:  Kaleigh E Lindholm; Peter A Forsberg; Mark D Ewalt
Journal:  EJHaem       Date:  2021-06-20

2.  Extrahepatic metabolism of ibrutinib.

Authors:  Johannes J M Rood; Amer Jamalpoor; Stephanie van Hoppe; Matthijs J van Haren; Roeland E Wasmann; Manoe J Janssen; Alfred H Schinkel; Rosalinde Masereeuw; Jos H Beijnen; Rolf W Sparidans
Journal:  Invest New Drugs       Date:  2020-07-04       Impact factor: 3.850
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.